Summarized by Masters of Longevity from Longevity Technology.
Companies will apply blood circRNA profiling to an Alzheimer's biomarker study.
Key Takeaways
- Circular Genomics will profile blood circRNA to assess baseline heterogeneity.
- The collaboration will track circRNA pathway changes during LM11A‑31 treatment.
- Expansion to other neurodegeneration programs and funding is being evaluated.
